CAnnaboid

Can-Fite BioPharma (NYSE: CANF) has completed pre-clinical studies demonstrating that a Cannabidiol (CBD)-rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth. The company's lead drug candidate Namodenoson is expected to enter the Phase 3 study in Q4...

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a nano-cap specialty pharmaceutical company that specializes in transdermal synthetic cannabinoid treatments for patients with high unmet needs, reported its second-quarter results Tuesday and also provided several key updates to ongoing...